
Presentation of the report
This report has been prepared in accordance with the Norwegian Transparency Act (the “Transparency Act”) section 5 and summarizes the policies and procedures in Nattopharma AS (“Nattopharma”) with respect to safeguarding of human rights and decent working conditions and provides information on the imolementation and results of NattoPharma’s due diligence.
View the 2022 Transparency Act Report
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...